Hence, the effects of combined BRAF/MEK inhibition in melanoma patients on immune responses should be synergistic or at least additive, thereby explaining the reported clinical benefits by combining immune checkpoint blocking antibodies with targeted therapy [6, 7, 25]. This evidence concerns the gene MAP2K7 and melanoma.